Novartis to Present Efficacy and Safety Data of Cosentyx and Investigational Remibrutinib at Major Dermatology Conferences
Novartis, a leading global medicines company, recently announced that it will present findings from 17 abstracts, including investigator-initiated trials, at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting. Two of these abstracts will focus on the long-term efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa (HS) and the impact of investigational remibrutinib on key clinical outcomes for patients with chronic spontaneous urticaria (CSU).
Two-year Data from Phase III SUNSHINE and SUNRISE Trials of Cosentyx in HS
The SUNSHINE and SUNRISE trials are Phase III studies that explored the long-term efficacy and safety of Cosentyx for HS. The data from these trials will be presented at the upcoming conferences. Hidradenitis suppurativa is a chronic, inflammatory skin condition characterized by the formation of painful and disfiguring lesions in areas where the skin folds, such as the armpits, groin, and under the breasts. Cosentyx, a monoclonal antibody, has been shown to provide significant improvements in symptoms, including reduced inflammation and the number of draining lesions. The two-year data from these trials will shed light on the long-term efficacy and safety of Cosentyx for HS management.
Impact of Investigational Remibrutinib on Key Clinical Outcomes for Patients with CSU
Another abstract will present 52-week data from the Phase III REMIX pivotal trials of investigational remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, for CSU. Chronic spontaneous urticaria is a skin condition characterized by the recurrent appearance of hives and itching, often with no known cause. The data from these trials will demonstrate the impact of remibrutinib on key clinical outcomes, such as the reduction of hives and itching, as well as the improvement in quality of life for patients with CSU. Remibrutinib is currently being developed as a potential treatment for this condition.
Regulatory Submissions for Remibrutinib as a Treatment for CSU On Track for Filing in 1H 2025
Novartis also announced that regulatory submissions for remibrutinib as a treatment for CSU are on track for filing in the first half of 2025. This means that, if approved, remibrutinib could become a new treatment option for patients with this condition. The data from the REMIX trials will be instrumental in supporting these regulatory submissions.
How Will This Affect Me?
If you have hidradenitis suppurativa or chronic spontaneous urticaria, the data presented at these conferences could have a significant impact on your treatment options. The long-term data on Cosentyx for HS could provide valuable insights into the safety and efficacy of this treatment for managing your condition. Additionally, the data on investigational remibrutinib for CSU could lead to the development of a new treatment option for managing your symptoms. It’s important to stay informed about the latest developments in your condition and to discuss any new treatment options with your healthcare provider.
How Will This Affect the World?
The presentation of these data at major dermatology conferences could lead to increased awareness and understanding of hidradenitis suppurativa and chronic spontaneous urticaria. The long-term data on Cosentyx and the potential new treatment option with remibrutinib could provide hope for those living with these conditions. Additionally, the regulatory submissions for remibrutinib could lead to a new treatment option for patients with CSU, potentially improving their quality of life. These advancements could also lead to increased investment in research and development for these conditions, ultimately leading to better treatments and a greater understanding of their underlying causes.
Conclusion
The upcoming American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting will see Novartis present data from 17 abstracts, including two focusing on the long-term efficacy and safety of Cosentyx for hidradenitis suppurativa and the impact of investigational remibrutinib on key clinical outcomes for chronic spontaneous urticaria. These data could lead to new treatment options and improved understanding of these conditions. For those living with hidradenitis suppurativa or chronic spontaneous urticaria, it’s important to stay informed about the latest developments and to discuss any new treatment options with your healthcare provider.
- Novartis to present data from 17 abstracts at AAAAI and AAD conferences
- Two-year data from Phase III SUNSHINE and SUNRISE trials of Cosentyx for HS to be presented
- 52-week data from Phase III REMIX trials of investigational remibrutinib for CSU to be presented
- Regulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025
- Long-term data on Cosentyx and potential new treatment option with remibrutinib could have significant impact on HS and CSU patients
- Stay informed about the latest developments and discuss any new treatment options with your healthcare provider
